Immunity, Inflammation and Disease Laboratory.
Inflammation and Innate Immunity Unit.
Am J Respir Cell Mol Biol. 2023 Dec;69(6):638-648. doi: 10.1165/rcmb.2023-0007OC.
Oxysterols (i.e., oxidized cholesterol species) have complex roles in biology. 25-Hydroxycholesterol (25HC), a product of the activity of cholesterol-25-hydroxylase (CH25H) on cholesterol, has recently been shown to be broadly antiviral, suggesting therapeutic potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, 25HC can also amplify inflammation and be converted by CYP7B1 (cytochrome P450 family 7 subfamily B member 1) to 7α,25-dihydroxycholesterol, a lipid with chemoattractant activity, via the G protein-coupled receptor EBI2 (Epstein-Barr virus-induced gene 2)/GPR183 (G protein-coupled receptor 183). Here, using studies and two different murine models of SARS-CoV-2 infection, we investigate the effects of these two oxysterols on SARS-CoV-2 pneumonia. We show that although 25HC and enantiomeric-25HC are antiviral against human endemic coronavirus-229E, they did not inhibit SARS-CoV-2; nor did supplemental 25HC reduce pulmonary SARS-CoV-2 titers in the K18-human ACE2 (angiotensin-converting enzyme 2) mouse model . Treatment with 25HC also did not alter immune cell influx into the airway, airspace cytokines, lung pathology, weight loss, symptoms, or survival but was associated with increased airspace albumin, an indicator of microvascular injury, and increased plasma proinflammatory cytokines. Conversely, mice treated with the EBI2/GPR183 inhibitor NIBR189 displayed a modest increase in lung viral load only at late time points but no change in weight loss. Consistent with these findings, although and 25HC were upregulated in the lungs of SARS-CoV-2-infected wild-type mice, lung viral titers and weight loss in and mice infected with the β variant were similar to those in control animals. Taken together, endogenous 25HCs do not significantly regulate early SARS-CoV-2 replication or pathogenesis, and supplemental 25HC may have proinjury rather than therapeutic effects in SARS-CoV-2 pneumonia.
氧化固醇(即氧化胆固醇)在生物学中具有复杂的作用。25-羟胆固醇(25HC)是胆固醇-25-羟化酶(CH25H)作用于胆固醇的产物,最近被证明具有广泛的抗病毒作用,这表明其具有针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的治疗潜力。然而,25HC 也可以放大炎症,并通过细胞色素 P450 家族 7 亚家族 B 成员 1(CYP7B1)转化为 7α,25-二羟胆固醇,后者是一种具有趋化活性的脂质,通过 G 蛋白偶联受体 EBI2(Epstein-Barr 病毒诱导基因 2)/GPR183(G 蛋白偶联受体 183)。在这里,我们使用研究和两种不同的 SARS-CoV-2 感染的小鼠模型,研究了这两种氧化固醇对 SARS-CoV-2 肺炎的影响。我们表明,尽管 25HC 和对映体-25HC 对人地方性冠状病毒-229E 具有抗病毒作用,但它们并没有抑制 SARS-CoV-2;补充 25HC 也没有降低 K18-human ACE2(血管紧张素转换酶 2)小鼠模型中的肺 SARS-CoV-2 滴度。25HC 的治疗也没有改变气道中的免疫细胞浸润、气腔细胞因子、肺病理学、体重减轻、症状或存活率,但与气腔白蛋白增加有关,气腔白蛋白是微血管损伤的指标,并且与血浆促炎细胞因子增加有关。相反,用 EBI2/GPR183 抑制剂 NIBR189 治疗的小鼠仅在晚期时间点肺部病毒载量略有增加,但体重减轻没有变化。与这些发现一致的是,尽管 SARS-CoV-2 感染野生型小鼠的肺组织中上调了 和 25HC,但感染 β 变体的 和 小鼠的肺病毒滴度和体重减轻与对照动物相似。综上所述,内源性 25HCs 不会显著调节 SARS-CoV-2 的早期复制或发病机制,补充 25HC 在 SARS-CoV-2 肺炎中可能具有促损伤而非治疗作用。